8-K Announcements
6Material company update
May 11, 2026·SEC
Material company update
Apr 17, 2026·SEC
Material company update
Mar 30, 2026·SEC
Pliant Therapeutics, Inc.(PLRX)Earnings, Financials & Key Ratios
PLRX•NASDAQ
$1.15
Price updated Jul 6, 2026
AboutPliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.Show more
- Revenue$0
- EBITDA-$148M+34.4%
- Net Income-$149M+29.0%
- EPS (Diluted)-2.43+30.0%
- ROE-61.55%-13.8%
PLRX Price & Volume
Pliant Therapeutics, Inc. (PLRX) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Liquidity Reserves
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent capital dilution risk
Key Thesis Takeaways
- Pliant Therapeutics faces a precarious financial outlook as it navigates late-stage clinical trials for bexotegrast without any recurring revenue to offset significant R&D expenditures.
- The company's reliance on stock-based compensation and debt financing to sustain operations suggests a high probability of near-term shareholder dilution.
- Investors should monitor the company's ability to secure non-dilutive capital or strategic partnerships, as the current cash burn trajectory appears unsustainable for long-term pipeline continuity.
Verdict Logic
the company's cash position of $22.2 million against a history of significant quarterly cash outflows suggests an imminent risk of dilutive financing to maintain operations.
PLRX Growth Metrics
Pliant Therapeutics, Inc. (PLRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM48.42%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM49.03%
Return on Capital
10 Years-100.31%
5 Years-47.92%
3 Years-50.59%
Last Year-52.42%
PLRX Recent Earnings
Pliant Therapeutics, Inc. (PLRX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 1/12 qtrs (50%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$0.32+11.1%
$0.36
Rev
—
—
Q2 2026
Mar 11, 2026Metric
Actual
Est
EPS
$0.35+16.7%
$0.42
Rev
—
$5M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.43+18.9%
$0.53
Rev
—
—
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.71-14.5%
$0.62
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.32vs $0.36+11.1% | — |
| Q2 2026 | Mar 11, 2026 | $0.35vs $0.42+16.7% | —vs $5M |
| Q4 2025 | Nov 6, 2025 | $0.43vs $0.53+18.9% | — |
| Q3 2025 | Aug 7, 2025 | $0.71vs $0.62-14.5% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Pliant Therapeutics, Inc. (PLRX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.15 | $71.21M | -0.47 | — | — | -61.55% | — | |
| $129.61 | $160.92B | 19.12 | 2.39% | 30.99% | 42.33% | — | |
| $39.37 | $3.46B | -30.76 | 3024.43% | -62.17% | -13.96% | — | |
| $80.78 | $9.58B | 31.55 | 37.55% | 23.13% | 126.27% | — | |
| $1.30 | $348.74M | -62.50 | 47.46% | -8.83% | -62.72% | — | |
| $21.82 | $1.61B | 6.61 | 18.52% | 118.91% | 47.59% | — |
Compare PLRX vs Peers
Pliant Therapeutics, Inc. (PLRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PLRX SEC Filings & Documents
Pliant Therapeutics, Inc. (PLRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when PLRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PLRX Frequently Asked Questions
Pliant Therapeutics, Inc. (PLRX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is PLRX profitable?
Pliant Therapeutics, Inc. (PLRX) reported a net loss of $113.2M for fiscal year 2025.
Dividend & Returns
What is PLRX's return on equity?
Pliant Therapeutics, Inc. (PLRX) has a return on equity (ROE) of -61.5%. Negative ROE indicates the company is unprofitable.
What is Pliant Therapeutics, Inc.'s free cash flow?
Pliant Therapeutics, Inc. (PLRX) had negative free cash flow of $98.8M in fiscal year 2025, likely due to heavy capital investments.